Anti-Human TIGIT [4E1.2] In Vivo Antibody - Low Endotoxin
Introducing the Anti-Human TIGIT [4E1-2] In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo applications. This antibody targets the TIGIT protein, an immunoreceptor expressed on T cells and natural killer (NK) cells, making it an invaluable tool for research in immunology and cancer immunotherapy.
With a mouse IgG2a kappa isotype, it ensures high purity and low endotoxin levels (<1.0 EU/mg), making it ideal for ELISA, flow cytometry, immunohistochemistry, and other assays. Available in various sizes, it is formulated in phosphate-buffered saline for stability and efficacy. Enhance your research with this reliable and versatile antibody. TIGIT is a co-inhibitory receptor that plays a crucial role in regulating immune responses. It is primarily expressed on activated T cells, memory T cells, and NK cells and interacts with its ligands, CD155 and CD112, to inhibit immune cell activation and proliferation. By modulating the immune response, TIGIT is involved in maintaining immune homeostasis and preventing autoimmunity, making it a significant target for therapeutic research and development.
Product Name:
Anti-Human TIGIT (Clone 4E1.2) In Vivo Antibody - Low Endotoxin
Product Code:
IVMB0267
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
4E1.2
Protein:
TIGIT
Product Type:
Monoclonal Antibody
Synonyms:
VSIG9, Vstm3, WUCAM
Isotype:
IgG3 k
Reactivity:
Human
Applications:
B, FC, In Vivo
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 200 mM arginine, 50 mM histidine, and 100 mM NaCl at a pH of 6.4 – 6.6, with no carrier protein, potassium or preservatives added Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
B, FC, In Vivo
Reactivity:
Human
Host Species:
Mouse
Specificity:
Clone 4E1.2 activity is directed against human TIGIT (WUCAM).
Antigen Distribution:
TIGIT is expressed on activated CXCR5+CD4+ T cells in peripheral blood, variably on CD8+ T cells and CD56+CD3- NK cells, and constitutively in tonsils on some CD3+CD8int T cells as well as the CXCR5high/ICOShigh subset of CD4+ T cells that contains fully differentiated TFH cells.
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 200 mM arginine, 50 mM histidine, and 100 mM NaCl at a pH of 6.4 – 6.6, with no carrier protein, potassium or preservatives added Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles. Note: This antibody is prone to precipitation at 2-8°C resulting in a slight opaque white liquid. At room temperature liquid is clear and colorless.
TIGIT (WUCAM) is an immunoreceptor that inhibits multiple immune cell responses, including T cell priming by dendritic cells, tumor cell killing by NK cells and cytotoxic T cells, and also enhances the immune suppressive activity of regulatory T cells1. TIGIT is a novel member of the Ig-superfamily distantly related to Nectins and Necls that aligns with the distal Ig-V-type domains of Nectin(1-4), poliovirus receptor (PVR; CD155), DNAM-1 (CD226), and TACTILE (CD96)2. TIGIT is preferentially expressed on human B helper follicular T cells and binds with high affinity to PVR under both static and flow conditions. Additionally, TIGIT, DNAM-1, and TACTILE are expressed together on T cells and NK cells and share PVR as a ligand1. TIGIT is not detectable on the surface of resting peripheral blood mononuclear cells from healthy donors unless activated2.
4E1.2 was generated by immunizing BALB/c mice with TIGITFLAG-Baf3 cells2. Baf3 cells transfected with TIGIT cDNA are specifically stained by 4E1.2. Blocking with 4E1.2 significantly reduces PVR-hFc binding to TIGIT/Baf3 and to ICOShigh CD4+ T cells. TIGIT-PVR interactions are important for regulating T cell function and contribute to T cell-dependent B cell responses.
TIGIT is an attractive target for cancer therapy due to its role as an immune checkpoint1. Immunotherapy targeting TIGIT and the PD-1/PD-L1 pathway is capable of tumor suppression. Other combinations, such as TIGIT with TIM-3, CD112R, or TACTILE, have also shown promise in blocking studies.
